title: Leuprolide acetate in the management of ureteral obstruction caused by endometriosis.
abstract: Endometriotic ureteral obstruction is a serious event commonly diagnosed late and therefore associated with a major risk of hydronephrotic renal atrophy. The standard therapy is surgical. However, medical treatment has been reported using danazol, progestins, and estrogen-progestin combinations, although solid documentation of the effect of hormonal therapy against ureteral endometriosis is lacking. Gonadotropin-releasing hormone (GnRH) agonist treatment of endometriosis has yielded good results but has not been adequately reported in patients with ureteric involvement. We report three patients treated with a GnRH agonist, leuprolide acetate, for 6-9 months as a preoperative course. One patient had bilateral and two had unilateral obstruction. The preoperative course relieved the obstruction in the patient with bilateral disease and in one with unilateral changes. The failure occurred in a patient with intrinsic ureteric endometriosis. This early experience suggests a place for GnRH agonist therapy for patients with ureteric obstruction due to endometriosis, probably, but not necessarily, in conjunction with a planned surgical procedure. If medical therapy is attempted, close surveillance of renal function is mandatory.
authors.affiliation: Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson.
authors.forename: M E
authors.initials: ME
authors.lastname: Rivlin
authors.forename: J D
authors.initials: JD
authors.lastname: Miller
authors.forename: R P
authors.initials: RP
authors.lastname: Krueger
authors.forename: R B
authors.initials: RB
authors.lastname: Patel
authors.forename: J D
authors.initials: JD
authors.lastname: Bower
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004715:Endometriosis / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006869:Hydronephrosis / Q000209:etiology; D016729:Leuprolide; D008875:Middle Aged; D010386:Pelvic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D011859:Radiography; D014516:Ureteral Neoplasms / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D014517:Ureteral Obstruction / Q000000981:diagnostic imaging / Q000209:etiology* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide